
Melanie E Royce MD
Hematology/Oncology
Professor, Internal Medicine, University of New Mexico School of Medicine
Join to View Full Profile
7605 Via de Calma NEAlbuquerque, NM 87113
Phone+1 505-264-2451
Dr. Royce is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1994 - 1997
- University of Cincinnati College of MedicineClass of 1994
Certifications & Licensure
- TX State Medical License 1997 - 2027
- NM State Medical License 2004 - 2021
- CT State Medical License 1996 - 1998
Clinical Trials
- Expanded Breast Cancer Registry and Tissue Repository Start of enrollment: 2006 Feb 16
- INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients Start of enrollment: 2023 Jul 31
- Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse Start of enrollment: 2007 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 57 citationsE2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer...Roisin M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz
Journal of Clinical Oncology. 2021-08-06 - 17 citationsTemporal trends in breast cancer survival by race and ethnicity: A population-based cohort study.Deirdre A. Hill, Eric R. Prossnitz, Melanie Royce, Andrea Nibbe
Plos One. 2019-10-24 - 77 citationsObesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics.Cindy K. Blair, Charles L. Wiggins, Andrea Nibbe, Curt B. Storlie, Eric R. Prossnitz
NPJ Breast Cancer. 2019-10-02
Press Mentions
- Everolimus plus Endocrine Therapy for Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical TrialJuly 1st, 2020
- Patient Selection an Important Next Step in HER2+ Breast CancerFebruary 4th, 2017
- Clinical Trial Finds Concurrent Therapy Not Necessary to Achieve High Pathological in Breast CancerFebruary 10th, 2016
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: